NeuroScientific Biopharmaceuticals Limited (NSB.AX)
AUD 0.04
(5.71%)
AUD 0.04
(5.71%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 44.24 Thousand | -2.3 Million | -6.94 Million | -2.6 Million | -2.28 Million | -1.4 Million |
| Net Income | 324.21 Thousand | -1.06 Million | -10.43 Million | -3.17 Million | -2.86 Million | -1.65 Million |
| Depreciation & Amortization | 91.33 Thousand | 57.85 Thousand | 64.91 Thousand | 61.4 Thousand | 56.66 Thousand | 55.2 Thousand |
| Deferred income taxes | - | -1.86 Million | 437.94 Thousand | -664.77 Thousand | -582.39 Thousand | - |
| Stock-based compensation | - | 242.74 Thousand | 1.35 Million | 625.85 Thousand | 496.03 Thousand | - |
| Change in working capital | -503.5 Thousand | -1.53 Million | 2.07 Million | -110.99 Thousand | 34.6 Thousand | -7806.00 |
| Other non-cash items | 826.46 Thousand | 1.86 Million | -437.94 Thousand | 664.77 Thousand | 582.39 Thousand | 204.1 Thousand |
| Investing Cash Flow | -1815.00 | - | -3866.00 | -29.87 Thousand | -2382.00 | -19.07 Thousand |
| Investments in PPE | -1815.00 | - | -3866.00 | -29.87 Thousand | -2382.00 | -19.07 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | 13.5 Million | 960.79 Thousand | 5.93 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 13.5 Million | 960.79 Thousand | 5.93 Million |
| Other Financing Activities | - | - | - | 13.5 Million | 960.79 Thousand | 5.93 Million |
| Accounts receivables | -11.01 Thousand | 77.46 Thousand | -71.53 Thousand | -30.26 Thousand | 8545.00 | -7806.00 |
| Accounts payables | -500.57 Thousand | -1.58 Million | 1.99 Million | 114.15 Thousand | 18.42 Thousand | 13.87 Thousand |
| Inventory | - | - | - | - | - | -204.1 Thousand |
| Other working capital | 8087.00 | -33.29 Thousand | 158.41 Thousand | -194.88 Thousand | 7630.00 | 190.23 Thousand |
| Cash at beginning of period | 4.91 Million | 7.21 Million | 14.16 Million | 3.28 Million | 4.6 Million | 103.89 Thousand |
| Cash at end of period | 4.95 Million | 4.91 Million | 7.21 Million | 14.16 Million | 3.28 Million | 4.6 Million |
| Capital Expenditure | -1815.00 | - | -3866.00 | -29.87 Thousand | -2382.00 | -19.07 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 42.43 Thousand | -2.3 Million | -6.94 Million | 10.87 Million | -1.32 Million | 4.5 Million |
| Free Cash Flow | 42.43 Thousand | -2.3 Million | -6.94 Million | -2.63 Million | -2.28 Million | -1.42 Million |
| Breakdown | 2024 FY | 2024 Q2 | 2023 Q4 | 2023 FY | 2023 Q2 | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 324.21 Thousand | -1.23 Million | 1.99 Million | -1.06 Million | -3.05 Million | -4.7 Million |
| Depreciation & Amortization | 91.33 Thousand | 42.43 Thousand | 27.85 Thousand | 57.85 Thousand | 30 Thousand | 33.01 Thousand |
| Deferred income taxes | - | - | -109.43 Thousand | -1.86 Million | - | -374.21 Thousand |
| Stock-based compensation | - | 104.72 Thousand | -23.72 Thousand | 242.74 Thousand | 266.47 Thousand | 379.72 Thousand |
| Change in working capital | -503.5 Thousand | - | 44.16 Thousand | -1.53 Million | - | 86.88 Thousand |
| Other non-cash items | 826.46 Thousand | -490.41 Thousand | -453.89 Thousand | 1.86 Million | -1.12 Million | 2.45 Million |
| Investing Cash Flow | -1815.00 | -1815.00 | - | - | - | -784.00 |
| Investments in PPE | -1815.00 | -1815.00 | - | - | - | -784.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | -11.01 Thousand | - | 77.46 Thousand | 77.46 Thousand | - | -71.53 Thousand |
| Accounts payables | -500.57 Thousand | - | - | -1.58 Million | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 8087.00 | - | -33.29 Thousand | -33.29 Thousand | - | 158.41 Thousand |
| Cash at beginning of period | 4.91 Million | 4.91 Million | 3.32 Million | 7.21 Million | 7.21 Million | 9.49 Million |
| Cash at end of period | 4.95 Million | 3.33 Million | 4.91 Million | 4.91 Million | 3.32 Million | 7.21 Million |
| Capital Expenditure | -1815.00 | -1815.00 | - | - | - | -784.00 |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 42.43 Thousand | -1.57 Million | 1.58 Million | -2.3 Million | -3.89 Million | -2.28 Million |
| Free Cash Flow | 42.43 Thousand | -1.57 Million | 1.58 Million | -2.3 Million | -3.89 Million | -2.28 Million |
INSECTICID
TCNT
RCI-A
BIGG
029460
1925